Search research articles
Contact Us
Filters
Showing results (1-10 of 99) with videos related to
Page
of 10
Sort By:
American Heart Journal
|
March 29, 2008
Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10)
Robert Wilcox, Stuart Kupfer, Erland Erdmann, et al.
Journal of Clinical Pharmacology
|
December 4, 2015
Population Pharmacokinetics and Exposure-Response of a Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With Stage 2 Hypertension
Max C Tsai, Jingtao Wu, Stuart Kupfer, et al.
Drug Safety
|
August 13, 2009
Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US
Keith G Tolman, James W Freston, Stuart Kupfer, et al.
Pharmacotherapy
|
September 27, 2006
Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus
Rajeev Jain, Kwame Osei, Stuart Kupfer, et al.
Psychosomatic Medicine
|
May 25, 2005
A Study of Antihypertensive Drugs and Depressive Symptoms (SADD-Sx) in patients treated with a calcium antagonist versus an atenolol hypertension Treatment Strategy in the International Verapamil SR-Trandolapril Study (INVEST)
L Douglas Ried, Michael J Tueth, Eileen Handberg, et al.
Journal of Hypertension
|
January 15, 2016
Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes
William B White, René H Cuadra, Eric Lloyd, et al.
Pharmacoepidemiology and Drug Safety
|
August 4, 2007
A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes
Charles M Gerrits, Mondira Bhattacharya, Shivaji Manthena, et al.
Journal of Cardiovascular Pharmacology
|
April 25, 2006
Metabolic syndrome, new onset diabetes, and new end points in cardiovascular trials
Steve M Haffner, Luis Ruilope, Björn Dahlöf, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)
|
November 10, 2005
A drug dose model for predicting clinical outcomes in hypertensive coronary disease patients
William J Elliott, Ann C Hewkin, Stuart Kupfer, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
May 8, 2026
Towards a Quantitative Understanding of Aficamten Clinical Pharmacology: Pharmacokinetic-Cardiodynamic Modeling to Support Safety and Efficacy
Justin D Lutz, Russ Wada, Daniel L Jacoby, et al.
Page
of 10
Search research articles
Search
Showing results (1-10 of 99) with videos related to
Sort By:
Page
of 10
American Heart Journal
|
March 29, 2008
Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10)
Robert Wilcox, Stuart Kupfer, Erland Erdmann, et al.
Journal of Clinical Pharmacology
|
December 4, 2015
Population Pharmacokinetics and Exposure-Response of a Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With Stage 2 Hypertension
Max C Tsai, Jingtao Wu, Stuart Kupfer, et al.
Drug Safety
|
August 13, 2009
Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US
Keith G Tolman, James W Freston, Stuart Kupfer, et al.
Pharmacotherapy
|
September 27, 2006
Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus
Rajeev Jain, Kwame Osei, Stuart Kupfer, et al.
Psychosomatic Medicine
|
May 25, 2005
A Study of Antihypertensive Drugs and Depressive Symptoms (SADD-Sx) in patients treated with a calcium antagonist versus an atenolol hypertension Treatment Strategy in the International Verapamil SR-Trandolapril Study (INVEST)
L Douglas Ried, Michael J Tueth, Eileen Handberg, et al.
Journal of Hypertension
|
January 15, 2016
Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes
William B White, René H Cuadra, Eric Lloyd, et al.
Pharmacoepidemiology and Drug Safety
|
August 4, 2007
A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes
Charles M Gerrits, Mondira Bhattacharya, Shivaji Manthena, et al.
Journal of Cardiovascular Pharmacology
|
April 25, 2006
Metabolic syndrome, new onset diabetes, and new end points in cardiovascular trials
Steve M Haffner, Luis Ruilope, Björn Dahlöf, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)
|
November 10, 2005
A drug dose model for predicting clinical outcomes in hypertensive coronary disease patients
William J Elliott, Ann C Hewkin, Stuart Kupfer, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
May 8, 2026
Towards a Quantitative Understanding of Aficamten Clinical Pharmacology: Pharmacokinetic-Cardiodynamic Modeling to Support Safety and Efficacy
Justin D Lutz, Russ Wada, Daniel L Jacoby, et al.
Page
of 10